Peptide Modifications: N-Termini, C-Termini, Amino Acids

A peptide sequence is often written as a simple row of amino-acid abbreviations. That sequence is essential, but it may not completely define the molecule.

Two materials can contain the same ordered amino-acid residues while differing at one of their terminal groups, at an amino-acid side chain, or through a bond connecting two parts of the sequence. These differences can affect molecular mass, charge, chromatographic behavior, solubility, and analytical interpretation.

For this reason, a complete peptide description should identify both the amino-acid sequence and any structural modifications.

The two ends of a peptide

A conventional linear peptide has two chemically distinct ends.

The N-terminus, or amino terminus, is the end containing the first amino-acid residue. The C-terminus, or carboxyl terminus, is the end containing the final residue. By convention, peptide sequences are written from the N-terminus on the left to the C-terminus on the right, and IUPAC-IUB nomenclature follows the same direction.[1]

For example: H-Ala-Gly-Ser-OH

H- represents a free N-terminal amino group.
-OH represents a free C-terminal carboxyl group.
Ala is the first, or N-terminal, residue.
Ser is the final, or C-terminal, residue.

The same three-residue sequence could also be produced with one or both ends modified.

What is N-terminal acetylation?

N-terminal acetylation adds an acetyl group to the amino group at the N-terminus. A modified sequence may be written as Ac-Ala-Gly-Ser-OH, where Ac indicates that the terminal amino group has been acetylated. Chemically, this converts the free terminal amine into an amide.

N-terminal acetylation therefore changes more than the label attached to the sequence. It changes the molecular formula, increases the molecular mass by approximately 42.01 daltons, and removes the ordinary basic behavior of the free terminal amino group.

Because charge affects interactions with chromatographic stationary phases, solvents, counterions, and other molecules, an acetylated peptide should not be treated as analytically identical to its non-acetylated counterpart.

What is C-terminal amidation?

C-terminal amidation converts the terminal carboxylic-acid group into an amide. An amidated sequence may be represented as H-Ala-Gly-Ser-NH₂.

IUPAC recognizes a C-terminal residue as one that does not acylate another amino-acid residue, and notes that the terminal carboxyl group may instead acylate ammonia to form a terminal amide.[1]

Amidation changes the terminal group from -COOH to -CONH₂. This changes the molecular formula and lowers the molecular mass by approximately 0.98 dalton relative to the corresponding free acid.

More importantly, amidation removes the ionizable terminal carboxyl group. The resulting change in charge can affect:

Electrophoretic mobility
Ion-exchange chromatography
Reversed-phase retention
Solubility under particular conditions
Association with counterions
Mass-spectrometric ionization patterns

The practical effect depends on the complete sequence, pH, solvent, concentration, and analytical method.

Can both termini be modified?

Yes. A peptide can be both N-terminally acetylated and C-terminally amidated: Ac-Ala-Gly-Ser-NH₂.

This molecule contains the same three amino-acid residues as the unmodified form, but it is not the same chemical substance.

Blocking both termini can also make a short synthetic peptide resemble an internal segment of a larger protein. An internal protein fragment normally does not possess a free amino group and free carboxyl group at the positions where it was originally connected to neighboring residues.

That does not mean terminal blocking is automatically appropriate for every experiment. The correct form depends on the structure being modeled and the requirements of the particular analytical procedure.

Side-chain modifications

Amino acids contain side chains that distinguish one residue from another. Some side chains can be chemically modified without changing the order of the peptide sequence. Common research examples include:

Phosphorylation of serine, threonine, or tyrosine
Acetylation or methylation of lysine
Oxidation of methionine
Formation of pyroglutamate at an N-terminal glutamine or glutamic-acid residue
Addition of carbohydrate groups
Attachment of fluorescent dyes or affinity labels
Incorporation of fatty acids or other lipid groups
Addition of polyethylene glycol or another polymer
Isotopic labeling
Replacement with a nonstandard or D-amino acid

Each modification changes some combination of molecular formula, mass, charge, hydrophobicity, conformation, or chemical reactivity.

Modified residues must therefore be explicitly identified. A sequence listing alone may not reveal whether a lysine residue is acetylated, whether a serine is phosphorylated, or whether a methionine has undergone oxidation.

Disulfide bonds

Two cysteine residues can form a covalent disulfide bond through their sulfur-containing side chains. This may occur between two positions within one peptide, between two separate peptide chains, or between a peptide and another cysteine-containing molecule.

Formation of one disulfide bond removes two hydrogen atoms from the combined structure. The molecular mass of the oxidized form is therefore approximately 2.02 daltons lower than the corresponding fully reduced thiol form.

The positions of the linked cysteines matter. Peptides containing several cysteine residues may form more than one possible disulfide arrangement, sometimes called disulfide connectivity or disulfide topology.

A mass measurement may confirm that oxidation occurred but may not, by itself, prove which cysteine is connected to which. Additional fragmentation, enzymatic mapping, or other structural methods may be needed.

D-amino acids and stereochemistry

Most naturally encoded peptide sequences are described using L-amino acids. Synthetic peptides can also contain D-amino acids, which are mirror-image stereoisomers.

Replacing an L-residue with the corresponding D-residue does not ordinarily change the molecular formula or nominal molecular mass. Basic mass spectrometry may therefore be unable to distinguish the two forms by intact mass alone.

The change can nevertheless affect conformation, chromatography, enzymatic susceptibility, and molecular recognition. Specialized chiral analytical methods may be needed. One published approach hydrolyzes the peptide and then evaluates amino-acid enantiomeric purity by direct chiral HPLC with electrospray tandem mass spectrometry, recovering D-substitutions across 19 chiral amino acids at levels of roughly 0.1 to 1.0 percent.[2]

Why modifications matter for mass spectrometry

Before interpreting a mass spectrum, the analyst must calculate the expected molecular mass of the exact proposed structure. That calculation should account for:

The complete amino-acid sequence
Free or modified terminal groups
Disulfide bonds
Side-chain modifications
Isotopic labels
Covalently attached linkers or tags
Any intended conjugated group

For example, a mass matching the unmodified free-acid peptide would not confirm the identity of an intended C-terminal amide. Likewise, a mass consistent with oxidation may indicate an intended disulfide bond, unintended methionine oxidation, or another structural change unless further evidence distinguishes them.

Why modifications matter for chromatography

Structural modifications can alter how a peptide interacts with the chromatographic system.

Changes in hydrophobicity may alter reversed-phase retention time. Changes in charge may affect ion-exchange chromatography, peak shape, and interactions with mobile-phase ion-pairing agents. Terminal modifications can also change how a peptide performs as a substrate in a purpose-built assay: in one mass-spectrometric endopeptidase assay, acetylating and amidating the substrate termini measurably improved detection.[3]

A reference chromatogram is therefore most useful when it was generated using the same molecular form as the sample. Retention time from an unmodified peptide should not automatically be applied to a terminally modified analogue.

How should a modified peptide be documented?

A useful technical description may include:

Full sequence: written from N-terminus to C-terminus
Terminal form: free amine, acetylated, formylated, amidated, or otherwise modified
Modified-residue positions: the exact location of phosphorylation, methylation, labeling, oxidation, or another alteration
Stereochemistry: identification of any D-amino acids or nonstandard residues
Disulfide connectivity: the cysteine residues forming each intended bond
Molecular formula: calculated for the defined covalent structure
Theoretical mass: monoisotopic, average, or both, clearly identified
Observed mass: reported with the analytical technique and ion assignment
Counterion or salt form: documented separately from covalent modifications

Are modifications always intentional?

No. Some modifications are deliberately introduced during peptide design or synthesis. Others can arise as impurities or degradation products. Examples of potentially unintended changes include:

Methionine or tryptophan oxidation
Deamidation of asparagine or glutamine
Aspartate isomerization
Incomplete removal of protecting groups
Formation of unintended disulfide bonds
N-terminal cyclization
Acylation caused by reagents or solvents
Racemization at susceptible residues

FDA guidance concerning synthetic peptide characterization emphasizes that peptide-related impurities can differ from the intended peptide through amino-acid changes, chemical modifications, or alterations introduced during synthesis and storage.[4] Several of these pathways are also sequence-dependent, as covered in our article on why peptide stability is sequence-dependent.

Key takeaway

A peptide is defined by more than its amino-acid sequence.

The terminal groups, residue stereochemistry, side-chain modifications, disulfide bonds, and conjugated groups all contribute to the identity of the molecule. Accurate documentation should specify these features and use analytical methods capable of distinguishing the intended form from closely related alternatives.

References

IUPAC-IUB: Nomenclature and Symbolism for Amino Acids and Peptides, sections 3AA-11 to 3AA-13 - N-terminal-left convention and the definition of a C-terminal residue.
Strege MA, Oman TJ, Risley DS, et al. Enantiomeric purity analysis of synthetic peptide therapeutics by direct chiral HPLC-ESI-MS/MS. J Chromatogr B 2023;1219:123638. PMID: 36857849.
Wang D, Baudys J, Ye Y, et al. Improved detection of botulinum neurotoxin serotype A by Endopep-MS through peptide substrate modification. Anal Biochem 2013;432(2):115-123. PMID: 23017875.
FDA: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (Guidance for Industry, CDER, 2021).

Peptide Modifications Explained: N-Termini, C-Termini, and Modified Amino Acids